Abstract
Ivosidenib (AG-120) in Mutant IDH1 AML and Advanced Hematologic Malignancies: Results of a Phase 1 Dose Escalation and Expansion Study
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
https://doi.org/10.1182/blood.v130.suppl_1.725.725
Copy DOIJournal: Blood | Publication Date: Dec 7, 2017 |
Citations: 19 |
Ivosidenib (AG-120) in Mutant IDH1 AML and Advanced Hematologic Malignancies: Results of a Phase 1 Dose Escalation and Expansion Study
Join us for a 30 min session where you can share your feedback and ask us any queries you have